{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.6","upperLimit":"16","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"PFS: Defined as the time from the date of first study treatment to the date of the first documented disease progression, by Response Evaluation Criteria in Solid Tumors (RECIST 1.0) guidelines, or death due to any cause. Progressive Disease (PD): at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"The investigational drug used in this study is pasireotide long acting release (LAR) 60 mg.\n\nPasireotide Long Acting Release (LAR): Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"Pasireotide LAR Treatment"}],"paramType":"MEDIAN","populationDescription":"Evaluable participants","reportingStatus":"POSTED","timeFrame":"12 months","title":"Progression-free Survival (PFS) at One Year","type":"PRIMARY","unitOfMeasure":"months"}